secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2022-06-21T23:59:59+00:00
Accession:  0001437749-22-015503
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 9.01, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma appoints Damon DeSantis to Board, replacing Carl DeSantis
------------------------------------------------------------------------------

- Carl DeSantis resigned as Class I Director on June 20, 2022; no disagreement cited.
- Damon DeSantis appointed to fill vacancy, will serve as Class I Director until 2024.
- Damon is son of Carl DeSantis, a principal shareholder, and serves on boards of MacPherson's and Celsius Holdings (CELH).
- Damon received a stock option for 50,000 shares at closing price on June 27, 2022, vesting quarterly through June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922015503/0001437749-22-015503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922015503/inbp20220620_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-015503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer